Casa
asdas

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Por um escritor misterioso

Descrição
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. - Abstract - Europe PMC
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study, Arthritis Research & Therapy
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
PDF] ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study, Arthritis Research & Therapy
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
ASDAS calculator - ASAS
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
AS Criteria: Diagnosis (ASAS), Disease Activity (ASDAS), Radiographic Progression (mSASSS) - Arthritis Rheumatism
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Disease Control Data, Ankylosing Spondylitis
de por adulto (o preço varia de acordo com o tamanho do grupo)